Use of estrogen antagonists and aromatase inhibitors in endometriosis
Review
OA: closed
CC0
⤵ 22 in-corpus citations
AI-generated summary
Aromatase inhibitors and anti-estrogens like raloxifene are being explored as novel treatments for endometriosis, a disorder dependent on estrogen, due to high aromatase expression in endometriotic implants.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Endometriosis is an estrogen-dependent disorder mostly occurring in reproductive-age women. Various therapies have been used in an attempt to treat endometriosis, including ovarian suppression therapy, surgical treatment or a combination of these strategies. However, in general, substantial surgery remains the primary treatment option for endometriosis at all stages. Recently, aromatase inhibitors and anti-estrogens have been proposed as novel potential candidates. The rationale for the use of aromatase inhibitors is mostly related to the high aromatase expression in endometriotic cysts and extra-ovarian endometriotic implants. Among anti-estrogens, raloxifene has been investigated in animal models with good results, but in premenopausal women, the compound does not seem to suppress estrogen production.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (22)
- A Systematic Review of Systematic Reviews on the Use of Aromatase Inhibitors for the Treatment of Endometriosis: The Evidence to Date 2023
- Pharmacology of Endometriosis 2021
- Predictive biomarkers may allow precision therapy of endometriosis 2017
- The Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety 2015
- Use of aromatase inhibitors in practice of gynecology 2015
- Anti-TNF-α treatment for pelvic pain associated with endometriosis 2013
- Progesterone Resistance, Aromatase, and Inflammation: The Important Relationships Between Hormones and Inflammation 2012
- Pentoxifylline for endometriosis 2012
- Activation of mutated K-ras in donor endometrial epithelium and stroma promotes lesion growth in an intact immunocompetent murine model of endometriosis 2011
- Anti-TNF-alpha treatment for pelvic pain associated with endometriosis 2010
- Pentoxifylline versus medical therapies for subfertile women with endometriosis 2009
- Pentoxifylline versus medical therapies for subfertile women with endometriosis 2009
- Endometriosis: current therapies and new pharmacological developments 2009
- Anti-TNF-α treatment for pelvic pain associated with endometriosis 2009
- Inflammation in the uterus induces phosphorylated extracellular signal-regulated kinase and substance P immunoreactivity in dorsal root ganglia neurons innervating both uterus and colon in rats 2008
- Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis 2008
- Alternative Therapieoptionen bei Endometriose 2007
- Der derzeitige Stand der konservativen Therapie der Endometriose 2006
- Subcutaneous Depot Medroxyprogesterone Acetate versus Leuprolide Acetate in the Treatment of Endometriosis-Associated Pain 2006
- Advances in the management of endometriosis: an update for clinicians 2005
- Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain 2005
- Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers? 2005
Source provenance
- europepmc
- last seen: 2026-10-16T06:09:50.462052+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:02:12.072533+00:00
License: CC0
· commercial use OK